Nicotinamide Riboside Clinical Trial for GWI

Gulf War Illness Clinical Trial

Official title:

A Randomized Double-blind Placebo-controlled Clinical Trial of Nicotinamide Riboside for Restoring Mitochondrial Bioenergetics in Gulf War Illness

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05243290
• Other study ID #: RI-NR-001
• Status: Recruiting
• Phase: N/A
• Start date: April 13, 2022
• Est. completion date: February 15, 2025

Study information

• Verified date: September 2023
• Source: Roskamp Institute Inc.
• Contact: Dakota Helgager
• Phone: 9412568019
• Email: dhelgager[@]roskampclinic.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this multi-site trial, we will use a randomized, double-blind, placebo-controlled study design to test whether 300 mg of Nicotinamide Riboside (NR) can achieve the primary objective of increasing plasma NAD+ levels in participants with Gulf War Illness (GWI).

Description:

The 1991 Gulf War (GW) was fought by a coalition of 30 countries that included 700,000 U.S. troops. Although the war itself lasted two months, adverse health consequences from this conflict are still experienced by GW veterans. Soon after their return, many soldiers started reporting multiple, seemingly unrelated symptoms, such as memory impairment, fatigue, gastrointestinal problems, and widespread pain. This illness, termed Gulf War Illness (GWI), affects about 32% of GW veterans. Several preclinical studies suggest the presence of bioenergetic deficits in the blood and brains of veterans with GWI, as well as in the mouse models of this illness. The investigators' recent work shows that plasma levels of bioenergetic metabolites, such as nicotinamide adenine dinucleotide (NAD+), are lower in veterans with GWI compared to healthy GW controls. This corresponds with low Sirt1 levels in the peripheral blood mononuclear cells (PBMC) from veterans with GWI. Given the importance of NAD+ in cellular bioenergetics, various approaches have been explored for supplementing NAD+. Among these, supplementation with the NAD+ precursor nicotinamide riboside (NR) appears to be a viable option, since this form of NAD+ can enter the cell and cross the blood-brain-barrier. The investigators' recent animal studies show that supplementation with NR, a member of the vitamin B3 family, can correct the bioenergetic deficits in GWI mice, which corresponds with an improvement in fatigue-type behavior that is commonly reported by veterans with GWI. The main objective of this project is to determine, through the use of metabolomics and biochemical assays, if NR supplementation can maintain a healthy bioenergetic profile in the blood of veterans with GWI. The secondary objective is to determine if NR can maintain healthy blood lipid and immune biomarker profiles in GWI veterans. The study will also explore whether NR can improve general health and well-being of veterans with GWI.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 52
• Est. completion date: February 15, 2025
• Est. primary completion date: February 15, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 47 Years to 70 Years

Eligibility

Inclusion Criteria:

• Both sexes, all ethnic groups, and ages 47 to 70 years.

• Subject willing and able to give informed consent.

• Medically stable as per the investigator's discretion.

• Negative urine pregnancy test for females of childbearing potential. A woman is considered of childbearing potential unless she is surgically sterile (hysterectomy or tubal ligation) or is postmenopausal (no menstrual cycle for 2 years or more).

• If female of childbearing potential, must be willing to use adequate birth control during the study and for 30 days after the last dose. Females agreeing to take an acceptable form of birth control per investigator discretion (where relevant). Females must prevent pregnancy or otherwise be unable to conceive.

• Veterans deployed to the Gulf War between August 1990 and August 1991.

• Veteran meets criteria for the CDC Chronic Multisymptom Illness (CMI) GWI definition or Kansas GWI definition.

• Weight of 50.0kg - 200.0kg (110 lbs. - 440 lbs.).

Exclusion Criteria:

• Diagnosed by a physician with medical or psychiatric conditions that would account for their symptoms or interfere with their ability to report their symptoms, as per investigator discretion.

• Female subject is either pregnant or nursing; or if female subject is of childbearing age is not currently on or is unwilling and/or unable to use birth control.

• Have contraindications, allergy, or sensitivity to NR, vitamin B3, or excipients (microcrystalline cellulose, silicon dioxide, magnesium stearate, hypromellose, and/or titanium dioxide).

• Any significant medical condition that could interfere with study conduct, as per investigator discretion. These may include but are not limited to the following: untreated chronic hypertension (defined as systolic > 180 mmHg; diastolic >110 mmHg), myocardial infarction within 6 months of screening, renal failure, hepatic failure, and/or receiving chemotherapy.

• Clinically significant lab values for clinical laboratory assessments, as per investigator discretion.

• Poor venous access.

• Current use of any NR supplement products (such as nicotinamide, nicotinamide mononucleotide (NMN), vitamin B3/Niacin, vitamin B complex, etc.) within 30 days of screening.

• Participation in another clinical trial involving dietary or pharmaceutical intervention within 90 days of screening.

Related Conditions & MeSH terms

• Gulf War Illness

Intervention

Dietary Supplement:
• Nicotinamide Riboside
The product under investigation, Nicotinamide riboside (NR), is a naturally occurring NAD+ precursor and a member of the vitamin B3 family.
• Placebo
Visually matching placebo capsules will contain the same inactive ingredients present in the manufactured NR capsules, with the exception of any NR compound.

Locations

Country	Name	City	State
United States	Nova Southeastern University	Fort Lauderdale	Florida
United States	The Roskamp Institute	Sarasota	Florida

Sponsors (3)

Lead Sponsor	Collaborator
Roskamp Institute Inc.	Nova Southeastern University, United States Department of Defense

Country where clinical trial is conducted

United States, 

References & Publications (3)

Joshi U, Evans JE, Pearson A, Saltiel N, Cseresznye A, Darcey T, Ojo J, Keegan AP, Oberlin S, Mouzon B, Paris D, Klimas N, Sullivan K, Mullan M, Crawford F, Abdullah L. Targeting sirtuin activity with nicotinamide riboside reduces neuroinflammation in a GWI mouse model. Neurotoxicology. 2020 Jul;79:84-94. doi: 10.1016/j.neuro.2020.04.006. Epub 2020 Apr 25. — View Citation

Spector R, Johanson CE. Vitamin transport and homeostasis in mammalian brain: focus on Vitamins B and E. J Neurochem. 2007 Oct;103(2):425-38. doi: 10.1111/j.1471-4159.2007.04773.x. Epub 2007 Jul 20. — View Citation

White RF, Steele L, O'Callaghan JP, Sullivan K, Binns JH, Golomb BA, Bloom FE, Bunker JA, Crawford F, Graves JC, Hardie A, Klimas N, Knox M, Meggs WJ, Melling J, Philbert MA, Grashow R. Recent research on Gulf War illness and other health problems in veterans of the 1991 Gulf War: Effects of toxicant exposures during deployment. Cortex. 2016 Jan;74:449-75. doi: 10.1016/j.cortex.2015.08.022. Epub 2015 Sep 25. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Changes in fatigue	The study will use the Multidimensional Fatigue Inventory (MFI-20) to assess fatigue.	10 weeks
Other	Changes in memory (neurocognitive)	The study will use the CNS Vital Signs computerized neurocognitive assessment software to assess memory. The computerized test uses individual tests to comprise a neurocognitive index score that can be used to evaluate neurocognitive status.	10 weeks
Other	Changes in memory (neuropsychological)	The study will use the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) cognitive test to assess memory. The test incorporates immediate memory, visuospatial/constructional, language, attention, and delayed memory components to determine a total scaled score for neuropsychological status. This total score ranges from 200 to 800, with higher scores increasing the associated percentile.	10 weeks
Other	Changes in general well-being	The study will use the Quality of Life Scale (SF36) to assess quality of life.	10 weeks
Other	Changes in mood	The study will use the Profile of Mood States (POMS) to assess mood.	10 weeks
Other	Changes in pain	The study will use the McGill Pain Questionnaire (SF-MPQ) to assess pain.	10 weeks
Primary	Changes in plasma NAD+ levels	The primary objective is to determine if NR can increase plasma NAD+ levels in GWI veterans.	10 weeks
Secondary	Changes in lipid profiles	The secondary objective is to determine if NR can help maintain healthy blood lipid in the blood of veterans with GWI.	10 weeks
Secondary	Changes in immune biomarker profiles	The secondary objective is to determine if NR can help maintain normal cytokine levels in the blood of veterans with GWI.	10 weeks